Results
1 -
10 of
49The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation, Cancer Chemotherapy and Pharmacology The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences, Targeted Oncology Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery, BMC Cancer The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia, Targeted Therapy of Acute Myeloid Leukemia Atypical Teratoid/Rhabdoid Tumor (AT/RT), Pediatric Radiation Oncology Clinical Development of Anti-mitotic Drugs in Cancer, Cell Division Machinery and Disease The Pediatric Preclinical Testing Program, Tumor Models in Cancer Research Neuroendokrines Prostatakarzinom, Der Urologe Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer, Cancer Chemotherapy and Pharmacology Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase, Cancer Chemotherapy and Pharmacology